[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fasHAPSG67bRG_BljyjLAAV2wma5dG3VtT7_Pi132ZoU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":43,"rows":50},"University of Brasilia",[4],65,false,10,4,5714,6,52,[14,16,18,21,23,25,28,30],{"name":15,"count":9},"Electrical Stimulation",{"name":17,"count":9},"Healthy",{"name":19,"count":20},"Low Back Pain",3,{"name":22,"count":20},"Aging",{"name":24,"count":20},"Radiodermatitis",{"name":26,"count":27},"Chronic Low Back Pain",2,{"name":29,"count":27},"Leprosy",{"name":31,"count":27},"Hearing Loss",[33,38],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06040489","Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly","2024-06","Miltefosine 50mg",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02530697","The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil","2025-08","Meglumine antimoniate",[44,45,46,47,48,49],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[51,94,112,130,188,206,224,252,270,288,306,324,342,360,385,409,434,459,489,507,525,543,561,579],{"intervention":52,"totalTrials":27,"cells":53},"Liposomal Amphotericin B",{"EARLY_PHASE1":54,"PHASE1":57,"PHASE2":59,"PHASE3":61,"PHASE4":75,"NA":92},{"trials":55,"activeCount":56},[],0,{"trials":58,"activeCount":56},[],{"trials":60,"activeCount":56},[],{"trials":62,"activeCount":74,"soonestReadout":36},[63],{"nctId":34,"briefTitle":35,"status":64,"phases":65,"primaryCompletion":36,"completion":66,"start":67,"enrollment":68,"conditions":69,"interventions":72},"RECRUITING",[46,47],"2026-06","2022-06-22",100,[70,71],"Leishmaniasis; Brazilian","Leishmaniasis, Mucocutaneous",[37,73,52],"Pentoxifylline 400mg",1,{"trials":76,"activeCount":56},[77],{"nctId":78,"briefTitle":79,"status":80,"phases":81,"primaryCompletion":82,"completion":83,"start":84,"enrollment":85,"conditions":86,"interventions":88},"NCT01310738","Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil","TERMINATED",[48],"2014-10","2015-02","2011-02",378,[87],"Visceral Leishmaniasis",[89,90,91,91,89],"Antimoniate of N-methylglucamine","amphotericin B deoxycholate","Liposomal amphotericin B",{"trials":93,"activeCount":56},[],{"intervention":37,"totalTrials":74,"cells":95},{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":108,"NA":110},{"trials":97,"activeCount":56},[],{"trials":99,"activeCount":56},[],{"trials":101,"activeCount":56},[],{"trials":103,"activeCount":74,"soonestReadout":36},[104],{"nctId":34,"briefTitle":35,"status":64,"phases":105,"primaryCompletion":36,"completion":66,"start":67,"enrollment":68,"conditions":106,"interventions":107},[46,47],[70,71],[37,73,52],{"trials":109,"activeCount":56},[],{"trials":111,"activeCount":56},[],{"intervention":73,"totalTrials":74,"cells":113},{"EARLY_PHASE1":114,"PHASE1":116,"PHASE2":118,"PHASE3":120,"PHASE4":126,"NA":128},{"trials":115,"activeCount":56},[],{"trials":117,"activeCount":56},[],{"trials":119,"activeCount":56},[],{"trials":121,"activeCount":74,"soonestReadout":36},[122],{"nctId":34,"briefTitle":35,"status":64,"phases":123,"primaryCompletion":36,"completion":66,"start":67,"enrollment":68,"conditions":124,"interventions":125},[46,47],[70,71],[37,73,52],{"trials":127,"activeCount":56},[],{"trials":129,"activeCount":56},[],{"intervention":42,"totalTrials":9,"cells":131},{"EARLY_PHASE1":132,"PHASE1":134,"PHASE2":136,"PHASE3":149,"PHASE4":151,"NA":186},{"trials":133,"activeCount":56},[],{"trials":135,"activeCount":56},[],{"trials":137,"activeCount":74,"soonestReadout":41},[138],{"nctId":39,"briefTitle":40,"status":139,"phases":140,"primaryCompletion":41,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":146},"ACTIVE_NOT_RECRUITING",[46],"2026-08","2015-08",160,[145],"Leishmaniasis",[42,147,148],"Miltefosine","Pentoxifylline",{"trials":150,"activeCount":56},[],{"trials":152,"activeCount":56},[153,165,176],{"nctId":154,"briefTitle":155,"status":156,"phases":157,"primaryCompletion":158,"completion":159,"start":160,"enrollment":161,"conditions":162,"interventions":164},"NCT00317980","Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis","COMPLETED",[48],"2008-03","2008-12","2006-02",280,[163],"Cutaneous Leishmaniasis",[42,42],{"nctId":166,"briefTitle":167,"status":156,"phases":168,"primaryCompletion":169,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":175},"NCT00818818","Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients",[48],"2010-01","2010-04","2008-08",13,[174],"Localized Cutaneous Leishmaniasis",[42],{"nctId":177,"briefTitle":178,"status":156,"phases":179,"primaryCompletion":169,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":184},"NCT01032187","Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children",[48],"2010-07","2007-10",101,[87],[42,185],"Amphotericin B-deoxycholate",{"trials":187,"activeCount":56},[],{"intervention":147,"totalTrials":74,"cells":189},{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":200,"PHASE4":202,"NA":204},{"trials":191,"activeCount":56},[],{"trials":193,"activeCount":56},[],{"trials":195,"activeCount":74,"soonestReadout":41},[196],{"nctId":39,"briefTitle":40,"status":139,"phases":197,"primaryCompletion":41,"completion":141,"start":142,"enrollment":143,"conditions":198,"interventions":199},[46],[145],[42,147,148],{"trials":201,"activeCount":56},[],{"trials":203,"activeCount":56},[],{"trials":205,"activeCount":56},[],{"intervention":148,"totalTrials":74,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":218,"PHASE4":220,"NA":222},{"trials":209,"activeCount":56},[],{"trials":211,"activeCount":56},[],{"trials":213,"activeCount":74,"soonestReadout":41},[214],{"nctId":39,"briefTitle":40,"status":139,"phases":215,"primaryCompletion":41,"completion":141,"start":142,"enrollment":143,"conditions":216,"interventions":217},[46],[145],[42,147,148],{"trials":219,"activeCount":56},[],{"trials":221,"activeCount":56},[],{"trials":223,"activeCount":56},[],{"intervention":225,"totalTrials":74,"cells":226},"PB 6 doses - Rifampicin and Dapsone",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":250},{"trials":228,"activeCount":56},[],{"trials":230,"activeCount":56},[],{"trials":232,"activeCount":56},[],{"trials":234,"activeCount":56},[],{"trials":236,"activeCount":56},[237],{"nctId":238,"briefTitle":239,"status":156,"phases":240,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":246},"NCT00669643","Uniform Multidrug Therapy Regimen for Leprosy Patients",[48],"2012-09","2016-12-31","2007-02",859,[29],[225,247,248,249],"PB 6 doses - Rifampicin, Clofazimine and Dapsone","MB 12 doses - Rifampicin, Clofazimine and Dapsone","MB 6 doses - Rifampicin, Clofazimine and Dapsone",{"trials":251,"activeCount":56},[],{"intervention":247,"totalTrials":74,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":268},{"trials":255,"activeCount":56},[],{"trials":257,"activeCount":56},[],{"trials":259,"activeCount":56},[],{"trials":261,"activeCount":56},[],{"trials":263,"activeCount":56},[264],{"nctId":238,"briefTitle":239,"status":156,"phases":265,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":266,"interventions":267},[48],[29],[225,247,248,249],{"trials":269,"activeCount":56},[],{"intervention":248,"totalTrials":74,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":280,"NA":286},{"trials":273,"activeCount":56},[],{"trials":275,"activeCount":56},[],{"trials":277,"activeCount":56},[],{"trials":279,"activeCount":56},[],{"trials":281,"activeCount":56},[282],{"nctId":238,"briefTitle":239,"status":156,"phases":283,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":284,"interventions":285},[48],[29],[225,247,248,249],{"trials":287,"activeCount":56},[],{"intervention":249,"totalTrials":74,"cells":289},{"EARLY_PHASE1":290,"PHASE1":292,"PHASE2":294,"PHASE3":296,"PHASE4":298,"NA":304},{"trials":291,"activeCount":56},[],{"trials":293,"activeCount":56},[],{"trials":295,"activeCount":56},[],{"trials":297,"activeCount":56},[],{"trials":299,"activeCount":56},[300],{"nctId":238,"briefTitle":239,"status":156,"phases":301,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":302,"interventions":303},[48],[29],[225,247,248,249],{"trials":305,"activeCount":56},[],{"intervention":89,"totalTrials":74,"cells":307},{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":322},{"trials":309,"activeCount":56},[],{"trials":311,"activeCount":56},[],{"trials":313,"activeCount":56},[],{"trials":315,"activeCount":56},[],{"trials":317,"activeCount":56},[318],{"nctId":78,"briefTitle":79,"status":80,"phases":319,"primaryCompletion":82,"completion":83,"start":84,"enrollment":85,"conditions":320,"interventions":321},[48],[87],[89,90,91,91,89],{"trials":323,"activeCount":56},[],{"intervention":90,"totalTrials":74,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":334,"NA":340},{"trials":327,"activeCount":56},[],{"trials":329,"activeCount":56},[],{"trials":331,"activeCount":56},[],{"trials":333,"activeCount":56},[],{"trials":335,"activeCount":56},[336],{"nctId":78,"briefTitle":79,"status":80,"phases":337,"primaryCompletion":82,"completion":83,"start":84,"enrollment":85,"conditions":338,"interventions":339},[48],[87],[89,90,91,91,89],{"trials":341,"activeCount":56},[],{"intervention":185,"totalTrials":74,"cells":343},{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":350,"PHASE4":352,"NA":358},{"trials":345,"activeCount":56},[],{"trials":347,"activeCount":56},[],{"trials":349,"activeCount":56},[],{"trials":351,"activeCount":56},[],{"trials":353,"activeCount":56},[354],{"nctId":177,"briefTitle":178,"status":156,"phases":355,"primaryCompletion":169,"completion":180,"start":181,"enrollment":182,"conditions":356,"interventions":357},[48],[87],[42,185],{"trials":359,"activeCount":56},[],{"intervention":361,"totalTrials":74,"cells":362},"montelukast sodium",{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":371,"NA":383},{"trials":364,"activeCount":56},[],{"trials":366,"activeCount":56},[],{"trials":368,"activeCount":56},[],{"trials":370,"activeCount":56},[],{"trials":372,"activeCount":56},[373],{"nctId":374,"briefTitle":375,"status":156,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":382},"NCT00770900","Study to Evaluate the Inflammatory Cells Activity in Patients With Persistent Asthma Treated With Montelukast (0476-403)(COMPLETED)",[48],"2009-12","2008-09",83,[381],"Asthma",[361],{"trials":384,"activeCount":56},[],{"intervention":386,"totalTrials":74,"cells":387},"Urea cream based",{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":394,"PHASE4":405,"NA":407},{"trials":389,"activeCount":56},[],{"trials":391,"activeCount":56},[],{"trials":393,"activeCount":56},[],{"trials":395,"activeCount":56},[396],{"nctId":397,"briefTitle":398,"status":399,"phases":400,"primaryCompletion":401,"completion":402,"start":142,"enrollment":68,"conditions":403,"interventions":404},"NCT02251392","Evaluation of Therapeutic Efficacy in Use of Chamomilla Gel, Chamomilla Infuse and Urea in Radiodermatitis","UNKNOWN",[47],"2016-07","2016-12",[24],[386],{"trials":406,"activeCount":56},[],{"trials":408,"activeCount":56},[],{"intervention":410,"totalTrials":74,"cells":411},"Urea cream",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":430,"NA":432},{"trials":413,"activeCount":56},[],{"trials":415,"activeCount":56},[],{"trials":417,"activeCount":56},[],{"trials":419,"activeCount":56},[420],{"nctId":421,"briefTitle":422,"status":156,"phases":423,"primaryCompletion":424,"completion":425,"start":426,"enrollment":427,"conditions":428,"interventions":429},"NCT02247830","Management Radiodermatitis in Patients With Breast or Head and Neck Cancer",[47],"2017-05","2017-07","2015-07",48,[24],[410],{"trials":431,"activeCount":56},[],{"trials":433,"activeCount":56},[],{"intervention":435,"totalTrials":74,"cells":436},"Ginkgo Biloba Extract",{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":453,"PHASE4":455,"NA":457},{"trials":438,"activeCount":56},[],{"trials":440,"activeCount":56},[],{"trials":442,"activeCount":56},[443],{"nctId":444,"briefTitle":445,"status":156,"phases":446,"primaryCompletion":447,"completion":447,"start":448,"enrollment":449,"conditions":450,"interventions":452},"NCT01139281","The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans",[46],"2008-06","2007-06",15,[451,31],"Ototoxicity",[435],{"trials":454,"activeCount":56},[],{"trials":456,"activeCount":56},[],{"trials":458,"activeCount":56},[],{"intervention":460,"totalTrials":74,"cells":461},"Urea Dose A",{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":483,"PHASE4":485,"NA":487},{"trials":463,"activeCount":56},[],{"trials":465,"activeCount":56},[],{"trials":467,"activeCount":56},[468],{"nctId":469,"briefTitle":470,"status":156,"phases":471,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":477},"NCT02249884","Dose-Response Curve: Interventions to Prevent and Treat Radiodermatitis",[46],"2015-03","2015-11","2014-02",30,[24],[460,478,479,480,481,482],"Urea Dose B","Urea Dose C","Chamomile Dose A","Chamomile Dose B","Chamomile Dose C",{"trials":484,"activeCount":56},[],{"trials":486,"activeCount":56},[],{"trials":488,"activeCount":56},[],{"intervention":478,"totalTrials":74,"cells":490},{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":501,"PHASE4":503,"NA":505},{"trials":492,"activeCount":56},[],{"trials":494,"activeCount":56},[],{"trials":496,"activeCount":56},[497],{"nctId":469,"briefTitle":470,"status":156,"phases":498,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":499,"interventions":500},[46],[24],[460,478,479,480,481,482],{"trials":502,"activeCount":56},[],{"trials":504,"activeCount":56},[],{"trials":506,"activeCount":56},[],{"intervention":479,"totalTrials":74,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":519,"PHASE4":521,"NA":523},{"trials":510,"activeCount":56},[],{"trials":512,"activeCount":56},[],{"trials":514,"activeCount":56},[515],{"nctId":469,"briefTitle":470,"status":156,"phases":516,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":517,"interventions":518},[46],[24],[460,478,479,480,481,482],{"trials":520,"activeCount":56},[],{"trials":522,"activeCount":56},[],{"trials":524,"activeCount":56},[],{"intervention":480,"totalTrials":74,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":528,"activeCount":56},[],{"trials":530,"activeCount":56},[],{"trials":532,"activeCount":56},[533],{"nctId":469,"briefTitle":470,"status":156,"phases":534,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":535,"interventions":536},[46],[24],[460,478,479,480,481,482],{"trials":538,"activeCount":56},[],{"trials":540,"activeCount":56},[],{"trials":542,"activeCount":56},[],{"intervention":481,"totalTrials":74,"cells":544},{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":555,"PHASE4":557,"NA":559},{"trials":546,"activeCount":56},[],{"trials":548,"activeCount":56},[],{"trials":550,"activeCount":56},[551],{"nctId":469,"briefTitle":470,"status":156,"phases":552,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":553,"interventions":554},[46],[24],[460,478,479,480,481,482],{"trials":556,"activeCount":56},[],{"trials":558,"activeCount":56},[],{"trials":560,"activeCount":56},[],{"intervention":482,"totalTrials":74,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":573,"PHASE4":575,"NA":577},{"trials":564,"activeCount":56},[],{"trials":566,"activeCount":56},[],{"trials":568,"activeCount":56},[569],{"nctId":469,"briefTitle":470,"status":156,"phases":570,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":571,"interventions":572},[46],[24],[460,478,479,480,481,482],{"trials":574,"activeCount":56},[],{"trials":576,"activeCount":56},[],{"trials":578,"activeCount":56},[],{"intervention":580,"totalTrials":74,"cells":581},"Diazepam",{"EARLY_PHASE1":582,"PHASE1":593,"PHASE2":595,"PHASE3":597,"PHASE4":599,"NA":601},{"trials":583,"activeCount":56},[584],{"nctId":585,"briefTitle":586,"status":156,"phases":587,"primaryCompletion":588,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":592},"NCT05069779","Diazepam and Blood Pressure Regulation",[44],"2019-05-20","2017-08-01",40,[17],[580],{"trials":594,"activeCount":56},[],{"trials":596,"activeCount":56},[],{"trials":598,"activeCount":56},[],{"trials":600,"activeCount":56},[],{"trials":602,"activeCount":56},[]]